Innovus Pharma CEO Interviewed on CEOLIVE.Tv LA JO

LA JOLLA, Calif., Oct. 3, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company"), www.innovuspharma.com , (OTCBB: INNV ) today announced that Dr. Bassam Damaj, President & Chief Executive Officer of the Company, was recently interviewed on the financial news network, CEOLIVE.Tv. The interview is available at: www.ceonews.tv/innv

In the interview, Damaj highlighted the milestones achieved by the Company, its growth, the upcoming launch of its premature ejaculation topical treatment EjectDelay, the upcoming and signed commercial partnerships and short-term goals for Innovus Pharma, which include additional commercial partnerships, and plans for potentially listing the company on the NASDAQ exchange in 2014.

Damaj, who took the reins of Innovus as CEO in late January 2013, noted that the company's market cap grew from under $5M to close to $17 million year to date.

About Innovus Pharma

Innovus Pharma, headquartered in La Jolla, California, is an emerging pharmaceuticals company that delivers innovative and uniquely presented and packaged health solutions through its over-the-counter medicines and consumer and health products.

Innovus Pharma develops, in-licenses, acquires and markets proprietary sexual dysfunction, respiratory, dermatology and pain pharmaceutical products intended for better patient compliance and results. The Company is building a robust pipeline with a wide range of products, including EjectDelay™ for premature ejaculation, CIRCUMSerum™ to help in reduced penile sensitivity, APEAZ™ for arthritis pain relief and Xyralid™ for hemorrhoids pain relief, as well as product candidates across different phases of development.

EjectDelay™ is an over-the-counter ("OTC") U.S. Food and Drug Administration compliant proprietary topical treatment containing the drug benzocaine and indicated for delay of premature ejaculation. The drug typically works within minutes of application to the glans of the penis. In clinical trials, the application of benzocaine has been shown to delay premature ejaculation by several minutes.

APEAZ™ is an FDA-compliant, fast-acting and powerful arthritis pain relief cream, formulated to target the joints where arthritis resides. APEAZ™ is one of the most intensive over-the-counter ("OTC") topical treatments for pain relief available today. APEAZ™ is available in regular and extra-strength formulations. The product is designed to relieve: acute pain, arthritis pain, athletic injuries, muscle soreness and/or stiffness, muscle and joint pain, simple backache, strains and sprains.

For further information about Innovus Pharma, go to http://www.innovuspharma.com

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may be considered to be "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that may individually or mutually impact the matters described in this release for a variety of reasons, many of which are outside the control of Innovus Pharma. These risks and uncertainties include, but are not limited to Innovus Pharma's ability to raise sufficient capital to fund its operations and growth strategy, the continued willingness of members of the Board of Directors to fund the company on an interim basis, Innovus Pharma's ability to achieve its development, regulatory, commercialization and financial goals for its existing products EjectDelay™, CIRCUMSerum™ and Apeaz™, its ability to acquire additional products, and its ability to achieve development, regulatory, commercialization and financial goals for such additional products. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or the "Investors" section of Innovus Pharma's website at innovuspharma.com.

Kevin Holmes Chesapeake Group T: 410-825-3930